Cargando…
Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) i...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SMC Media Srl
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279911/ https://www.ncbi.nlm.nih.gov/pubmed/32523930 http://dx.doi.org/10.12890/2020_001731 |